Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor

Molecular Pharmacology

Volumn 68, Issue 1, 2005, Pages 20-33

  Setola, Vincent ^a   Dukat, Malgorzata ^b   Glennon, Richard A ^b   Roth, Bryan L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL GROUP; NORFENFLURAMINE; RECEPTOR PROTEIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; VALINE;

ARTICLE; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULE; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS;

APPETITE DEPRESSANTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART VALVE DISEASES; HUMANS; IMAGING, THREE-DIMENSIONAL; NORFENFLURAMINE; POINT MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN;

EID: 22344438896     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.009266     Document Type: Article

References (43)

1. Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth B, and Roth BL (2004) Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Gαq-coupled protein receptors. J Biol Chem 279:34614-34623.
2. Bigler TL, Lu W, Park SJ, Tashiro M, Wieczorek M, Wynn R, and Laskowski M Jr (1993) Binding of amino acid side chains to preformed cavities: interaction of serine proteinases with turkey ovomucoid third domains with coded and noncoded P1 residues. Protein Sci 2:786-799.
3. 3 receptors. U.S. patent 6,465,485. 2002 Oct 15.
4. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, and Simonneau G (1993) Primary pulmonary hypertension and fenfluramine use. Br Heart J 70:537-541.
5. 3H]ketanserin binding to 5-hydroxytryptamine2 receptors. Mol Pharmacol 43:755-761.
6. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, and Schaff HV (1997) Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 337:581-588.
7. Dengel F, Ehrmann O, Friedrich L, and Zimmermann F (1975) inventors; Knoll A.G. Chemische Fabriken, assignee. Theophylline derivatives. U.S. patent 3,926,995. 1975 Dec 16.
8. Faergeman NJ, Sigurskjold BW, Kragelund BB, Andersen KV, and Knudsen J (1996) Thermodynamics of ligand binding to acyl-coenzyme A binding protein studied by titration calorimetry. Biochemistry 35:14118-14126.
9. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, et al. (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81.
10. Fuller RW, Snoddy HD, Clemens JA, and Molloy BB (1982) Effect of norfenfluramine and two structural analogues on brain 5-hydroxyindoles and serum prolactin in rats. J. Pharm. Pharmacol. 34:449-450.
11. Glennon RA, Titeler M, and McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505-2511.
12. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, et al. (2002) Activation of central melanocortin pathways by fenfluramine. Science (Wash DC) 297:609-611.
13. Huang K, Lu W, Anderson S, Laskowski M Jr, and James MN (1995) Water molecules participate in proteinase-inhibitor interactions: crystal structures of Leu18, Ala18 and Gly18 variants of turkey ovomucoid inhibitor third domain complexed with Streptomyces griseus proteinase B. Protein Sci 4:1985-1997.
14. Kawaguchi S and Kuramitsu S (1998) Thermodynamics and molecular simulation analysis of hydrophobic substrate recognition by aminotransferases. J Biol Chem 273:18353-18364.
15. Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA, and Roth BL (2000) A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J Pharmacol Exp Ther 293:735-746.
16. Kroeze WK, Kristiansen K, and Roth BL (2002) Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem 2:507-528.
17. Kroeze WK, Sheffler DJ, and Roth BL (2003) G-protein-coupled receptors at a glance. J Cell Sci 116:4867-4869.
18. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135.
19. Lu W, Apostol I, Qasim MA, Warne N, Wynn R, Zhang WL, Anderson S, Chiang YW, Ogin E, Rothberg I, et al. (1997) Binding of amino acid side-chains to S1 cavities of serine proteinases. J Mol Biol 266:441-461.
20. Manivet P, Schneider B, Smith JC, Choi DS, Maroteaux L, Kellermann O, and Launay JM (2002) The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis. J Biol Chem 277:17170-17178.
21. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99 (Suppl): S18-S27.
22. Menicagli R and Samaritani S (1996) 1,4-Conjugate addition of the Reformatsky reagent to α-nitrostyrenes: a new synthesis of γ-nitroesters. Tetrahedron 52:1425-1432.
23. Morton A, Baase WA, and Matthews BW (1995) Energetic origins of specificity of ligand binding in an interior nonpolar cavity of T4 lysozyme. Biochemistry 34:8564-8575.
24. Moses PL and Wurtman RJ (1984) The ability of certain anorexic drugs to suppress food consumption depends on the nutrient composition of the test diet. Life Sci 35:1297-1300.
25. Neill JC and Cooper SJ (1989) Evidence that D-fenfluramine anorexia is mediated by 5-HT1 receptors. Psychopharmacology (Berl) 97:213-218.
26. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181.
27. Oue S, Okamoto A, Nakai Y, Nakahira M, Shibatani T, Hayashi H, and Kagamiyama H (1997) Paracoccus denitrificans aromatic amino acid aminotransferase: a model enzyme for the study of dual substrate recognition mechanism. J Biochem (Tokyo) 121:161-171.
28. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science (Wash DC) 289:739-745.
29. Pouwels HM, Smeets JL, Cheriex EC, and Wouters EF (1990) Pulmonary hypertension and fenfluramine. Eur Respir J 3:606-607.
30. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, and Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939.
31. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
32. Roth BL, Shoham M, Choudhary MS, and Khan N (1997) Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Mol Pharmacol 52:259-266.
33. Roth BL, Willins DL, Kristiansen K, and Kroeze WK (1998) 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 79:231-257.
34. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
35. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, and Roth BL (2003) 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229.
36. 2A serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol 58:877-886.
37. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, and Roth BL (2002) Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 277:11441-11449.
38. Shi L and Javitch JA (2004) The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 101:440-445.
39. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, and Herve P (1998) Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 114:195S-199S.
40. Steffee CH, Singh HK, and Chitwood WR (1999) Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8:245-253.
41. Tomita T and Zhao Q (2002) Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. Chest 121:649-652.
42. Vickers SP, Dourish CT, and Kennett GA (2001) Evidence that hypophagia induced by D-fenfluramine and D-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41:200-209.
43. Weintraub M, Sundaresan PR, Schuster B, Moscucci M, and Stein EC (1992) Longterm weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Clin Pharmacol Ther 51:602-607.